J Stroke Cerebrovasc Dis:他汀类药物能够降低LDL-C急性卒中患者的死亡率

2015-09-01 phylis 译 MedSci原创

为了调查住院患者他汀类药物治疗对低密度脂蛋白胆固醇(LDL-C<1.81 mmol/L)水平的急性卒中患者死亡率的影响。从中国国家登记表中招募急性卒中患者,患者LDL-C低于1.81 mmol/L。住院期间根据患者是否应用他汀类治疗,将患者分为他汀组和非他汀组。应用多变量二元logistic回归模型分析患者进行他汀类药物治疗和患者1年死亡率之间的关系。招募了1018名患者,3个月累积死亡率为

为了调查住院患者他汀类药物治疗对低密度脂蛋白胆固醇(LDL-C<1.81 mmol/L)水平的急性卒中患者死亡率的影响。

从中国国家登记表中招募急性卒中患者,患者LDL-C低于1.81 mmol/L。住院期间根据患者是否应用他汀类治疗,将患者分为他汀组和非他汀组。应用多变量二元logistic回归模型分析患者进行他汀类药物治疗和患者1年死亡率之间的关系。

招募了1018名患者,3个月累积死亡率为10.1%,6个月累积死亡率13.1%,1年的累积死亡率为15.9%。他汀组的死亡率低于非他汀组(3.6% versus 13.7% at 3 months; 6.2% versus 16.9% at 6 months; 8.4% versus 20% at 1 year)。Logistic分析表明住院期间,应用他汀类药物治疗与患者3个月(OR,0.35; 95% CI, 0.18-0.67),6个月(OR,0.42; 95% CI, 0.25-0.73),1年(OR,0.47; 95% CI, 0.29-0.76)的死亡率下降有关。

住院期间应用他汀类药物能够降低LDL-C急性卒中患者的死亡率。

原文出处:

Song B, Wang Y, Zhao X,et al. Inpatient Statin Use Is Associated with Decreased Mortality of Acute Stroke Patients with Very Low Low-Density Lipoprotein Cholesterol. J Stroke Cerebrovasc Dis. 2015 Aug 21. 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720052, encodeId=34ac1e200521d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Dec 23 13:17:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044380, encodeId=b3242044380a1, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Dec 11 20:17:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012008, encodeId=b8a5201200890, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jun 18 07:17:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938507, encodeId=e065193850ec9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Mar 24 05:17:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284432, encodeId=7b2f128443284, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422527, encodeId=d432142252e45, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720052, encodeId=34ac1e200521d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Dec 23 13:17:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044380, encodeId=b3242044380a1, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Dec 11 20:17:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012008, encodeId=b8a5201200890, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jun 18 07:17:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938507, encodeId=e065193850ec9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Mar 24 05:17:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284432, encodeId=7b2f128443284, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422527, encodeId=d432142252e45, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720052, encodeId=34ac1e200521d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Dec 23 13:17:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044380, encodeId=b3242044380a1, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Dec 11 20:17:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012008, encodeId=b8a5201200890, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jun 18 07:17:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938507, encodeId=e065193850ec9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Mar 24 05:17:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284432, encodeId=7b2f128443284, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422527, encodeId=d432142252e45, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720052, encodeId=34ac1e200521d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Dec 23 13:17:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044380, encodeId=b3242044380a1, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Dec 11 20:17:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012008, encodeId=b8a5201200890, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jun 18 07:17:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938507, encodeId=e065193850ec9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Mar 24 05:17:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284432, encodeId=7b2f128443284, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422527, encodeId=d432142252e45, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2016-03-24 quxin068
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720052, encodeId=34ac1e200521d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Dec 23 13:17:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044380, encodeId=b3242044380a1, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Dec 11 20:17:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012008, encodeId=b8a5201200890, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jun 18 07:17:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938507, encodeId=e065193850ec9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Mar 24 05:17:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284432, encodeId=7b2f128443284, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422527, encodeId=d432142252e45, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1720052, encodeId=34ac1e200521d, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Dec 23 13:17:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044380, encodeId=b3242044380a1, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Dec 11 20:17:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012008, encodeId=b8a5201200890, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jun 18 07:17:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938507, encodeId=e065193850ec9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Mar 24 05:17:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284432, encodeId=7b2f128443284, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422527, encodeId=d432142252e45, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Sep 03 00:17:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 zhwj

相关资讯

BMJ:NICE他汀类药物指南应公布需治疗人数及治疗风险

当以需治疗人数(NNT)作为评估他汀获益指标,而非ASCOT-LLA研究中所呈现的他汀治疗可以减少36%心血管疾病发生风险为参照时,他汀获益或许远非如此巨大。英国医学杂志应该质疑目前宣称的他汀治疗益处及其最小化的副作用。英国国家健康临床优化研究院(NICE)发布的指南草案影响力很大,因此必须准确而又通俗易懂地描述指南证据。明确的指南有助于全科医生等采用最佳基于证据的建议规劝患者服药。出于明确性和完

NEJM:PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平

Alirocumab是一种单克隆抗体,为前蛋白转化酶枯草溶菌素 9(PCSK9)抑制剂,先前有研究发现,Alirocumab可降低使用他汀类药物治疗的患者的低密度脂蛋白胆固醇(LDL-C)水平。Robinson JG等人进行了一项随机对照试验以探究Alirocumab的有效性和安全性。

ACC 2015:胆固醇理论的又一论证 OSLER研究延长期随访结果

作者:郭艺芳(河北省人民医院)胆固醇理论认为,胆固醇是动脉粥样硬化斑块的主要成分,没有胆固醇就没有动脉粥样硬化性心血管疾病。20余年来先后结束的大量临床研究证实,对于心血管患者及其高危人群,应用他汀类药物的主要作用机制仍存在争议。多数学者认为,他汀主要通过降低胆固醇水平发挥有益效应,但也有学者认为此类药物的多效性(抗炎、抗氧化应激、保护血管内皮功能等)起着关键作用。半个多世纪以来,多项临床试验均未

JAMA Oncology:他汀类药物有助于接受雄激素剥夺疗法的前列腺癌患者延缓疾病进展

一项由丹纳-法伯癌症研究中心研究人员开展的临床试验结果显示,对不接受他汀类药物治疗的男性患者,在进行雄激素剥夺治疗后的前列腺癌患者接受降胆固醇的他汀类药物治疗能够获得更长时间的疾病控制。在这项最新在线发表在JAMA Oncology杂志上的研究中,研究人员报告说,在接受雄激素剥夺疗法(ADT)开始服用他汀类药物的男性患者平均27.5个月后疾病开始恶化,而没有接受他汀类药物治疗的男性则仅有17.4个

Nat Commun:遗传突变会影响他汀类药物效应

近日,刊登在国际杂志Nature Communications上的一篇研究报告中,来自伦敦女王大学的科学家们通过对4万名进行他汀类药物治疗的患者的大型分析研究后鉴别出了两种新型的遗传突变,这两种遗传突变可以影响机体坏胆固醇对他汀类疗法的反应。 他汀类药物是临床中广泛使用的用于降低坏胆固醇的药物,其可将坏胆固醇水平降低至55%,从而可以有效减少心脏病的风险,尽管如此,不同病人对他汀类药物的

郭艺芳:降胆固醇治疗策略的新趋势

河北省人民医院 郭艺芳近日,有三则关于降胆固醇治疗的消息在各类媒体广泛传播:其一,IMPROVE-IT研究结果在新英格兰医学杂志正式发表;其二,选择性胆固醇吸收抑制剂临床应用中国专家共识正式发表;其三,FDA将就两种降胆固醇新药PCSK9抑制剂Alirocumab与Evolocumab举行专家听证会。综合分析这三则消息,可以看出降胆固醇的药物治疗策略正从他汀类药物一枝独秀的局面转变为以他汀为主、胆